Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 297

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 10
Chunk 297
---
Officers
and Directors

The
following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held
by each. Our Board of Directors elects our executive officers annually by majority vote. Each director’s term continues until his
or her successor is elected or qualified at the next annual meeting, unless such director earlier resigns or is removed. In addition,
the following table sets forth the names and ages of the members of our Science Advisory Board.

    Name
     
    Age 
     
    Position
  
    Executive
    Officers and Directors:

    Christer
    Rosén
     
    73
     
    Chairman
    of Board, Chief Executive Officer and Director
  
    Saleem
    Elmasri
     
    39
     
    Chief
    Financial Officer and Secretary
  
    Marshall
    Hayward, Ph.D.
     
    70
     
    Chief
    Scientific Officer and Director
  
    Alexander
    Rosén
     
    34
     
    Chief
    Administrative Officer
  
    Alison
    D. Silva
     
    46
     
    President,
    Chief Business Officer, and Director
  
    Nicholas
    H. Hemmerly
     
    42
     
    Independent
    Director
  
    Julie
    Kampf
     
    63
     
    Independent
    Director
  
    Allison
    W. Brady
     
    54
     
    Independent
    Director
  
    Holger
    Weis
     
    62
     
    Independent
    Director

94

Biographical
information concerning our executive officers and directors listed above is set forth below.

Executive
Officers

Christer
Rosén. Mr. Rosén is our Co-Founder and has served as our Chief Executive Officer and Chairman of our Board of Directors
since January 1, 2016. From 1997 through May 2015, Mr. Rosén founded and served as the Chief Executive Officer and Chairman of
EffRx Pharmaceuticals. Mr. Rosén together with Marshall Hayward, our Chief Scientific Officer, held the same position at EffRx,
invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto®. Binosto®
is distributed in several parts of the world and gave Mr. Rosén a full insight in all the aspects of pharmaceutical development,
regulatory paths and distribution